Main: +45 31 10 91 91
Fax: +45 77 31 15 09
CVR/VAT no. 31348854
Ordering: +45 29 13 42 24
This is an exciting opportunity for an individual with a knowledge of immune monitoring and single-cell technologies joining a globally active biotechnology company, Immudex, as a field application scientist.
Immudex is a growing company providing solutions for T and B cell immune monitoring within immunotherapy, transplantation, infections disease, and autoimmunity. Based on our proprietary Dextramer® technology, we develop and market research reagents and diagnostic assays enabling researchers, developers, and clinicians to measure disease-specific T cell responses.
The successful candidate will have the opportunity to become a subject matter expert in the application of immune monitoring technologies and travel extensively within North America for the purpose of supporting and maintaining our growing customer base.
Travel to/from the company headquarters in Copenhagen approximately once per quarter will be necessary.
Please apply to this position as soon as possible to firstname.lastname@example.org as we will process applications on an ongoing basis. For more information about the position, please contact Stephen Haley, Vice President AMER and Global Strategic Liaison, at (301) 606-9145 or email@example.com.
Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex is a fast-growing life science company providing solutions for immune monitoring within cancer immunotherapy, transplantation, infectious disease, and autoimmunity. With an off-set in Immudex' proprietary Dextramer® and dCODE Dextramer® technologies, the company develops and market research reagents and assay solutions enabling researchers and clinicians to measure disease-specific immunity. All Immudex' products are produced to the highest standards, resulting in reproducible monitoring over time. GMP grade and diagnostic Dextramer reagents are available and currently in use within the USA and Europe. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.